{
  "folder": "IC-027",
  "content": "{{knowledge objective\n|Identifiant=OIC-027-31-A\n|Item_parent=Prevention of foetal risks: infection, drugs, toxic substances, irradiation\n|Item_parent_short=Prevention of foetal risks: infection, drugs, toxic substances, irradiation\n|Rank=A\n|Intitul\u00e9=M\u00e9dicaments et grossesse : conna\u00eetre les principaux m\u00e9dicaments \u00e0 risque\n|Description=Knowing how to identify the main drugs at risk\n|Rubric=Positive diagnosis\n|Contributors=Alexandre Vivanti, Philippe Deruelle\n|Order=31}}\n\n{| class=\"wikitable\"\n|'''Family'''\n|'''INN (trade name)'''\n|-\n|Vitamin A derivatives\n|Isotretinoin\n\n(Roaccutane<sup>\u00ae</sup>, Acnetrait<sup>\u00ae</sup>, Curacne<sup>\u00ae</sup>, Procuta<sup>\u00ae</sup>)\n\nAcitretin\n\n(Soriatane<sup>\u00ae</sup>)\n|-\n|Thymoregulator\n|Lithium (T\u00e9ralithe<sup>\u00ae</sup>)\n|-\n|Oral anticoagulants, antivitamins K\n|Warfarin (Coumadin<sup>\u00ae</sup>)\n|-\n|Antiepileptics\n|Sodium valproate (Depakine<sup>\u00ae</sup>), carbamazepine (Tegretol<sup>\u00ae</sup>)\n|-\n|Prostaglandin analogue (PGE1)\n|Misoprostol (Gymiso<sup>\u00ae</sup>, Misoone<sup>\u00ae</sup>)\n|-\n|Immunosuppressant\n|Mycophenolate (Cellcept<sup>\u00ae</sup>, Myfortic<sup>\u00ae</sup>)\n|-\n|Cancer treatment\n|Methotrexate (Ledertrexate<sup>\u00ae</sup>, Imeth<sup>\u00ae</sup>)\n|-\n|Synthetic antithyroid drugs\n|Carbimazole, (Neo-Mercazole<sup>\u00ae</sup>)\n\nPTU (propylthio-uracil: Propylex<sup>\u00ae</sup>)\n|-\n|Virostatics\n|Ribavirin (Copegus<sup>\u00ae</sup>, Rebetol<sup>\u00ae</sup>)\n\nEfavirenz (Sustiva<sup>\u00ae</sup>)\n|}\n\n\n'''312. [[Prevention of foetal risks SD-312|Prevention of foetal risks]]''''\n\n'''340 [[Voluntary or involuntary intake of a toxic or potentially toxic drug SD-340|Voluntary or involuntary intake of a toxic or potentially toxic drug]]''''\n\n'''348. [Suspicion of an adverse drug reaction or an adverse drug treatment SD-348|Suspicion of an adverse drug reaction or an adverse drug treatment]'''''\n\n'''352. [[Explaining treatment to the patient (adult/child/adolescent) SD-352|Explaining treatment to the patient (adult/child/adolescent)]]'''''",
  "question": {
    "question": "Which of the following medications is considered a potential risk for fetal development due to its mechanism of action?",
    "option_a": "Acetaminophen (Tylenol)",
    "option_b": "Ibuprofen (Advil)",
    "option_c": "Sodium valproate (Depakine)",
    "option_d": "Aspirin",
    "correct_option": "c"
  }
}